CL2012000101A1 -
Pyridine derived compounds, s1p1 / edg1 receptor agonists, pharmaceutical composition; use of the compound for the treatment of diseases or disorders associated with the activated immune system such as organ rejection, autoimmune syndromes including rheumatoid arthritis, among others.
- Google Patents
Pyridine derived compounds, s1p1 / edg1 receptor agonists, pharmaceutical composition; use of the compound for the treatment of diseases or disorders associated with the activated immune system such as organ rejection, autoimmune syndromes including rheumatoid arthritis, among others.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals LtdfiledCriticalIdorsia Pharmaceuticals Ltd
Publication of CL2012000101A1publicationCriticalpatent/CL2012000101A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
COMPUESTOS DERIVADOS DE PIRIDINA, DE FORMULA (I) EN EL CUAL A, R1, R2, R3 Y R4 SON TAL COMO SE DEFINEN EN LA MEMORIA DESCRIPTIVA Y PLIEGO DE REIVINDICACIONES, AGONISTAS DEL RECEPTOR SLP1/EDG1; COMPOSICIÓN FARMACÉUTICA Y USO EN EL TRATAMIENTO DE ENFERMEDADES O TRASTORNOS TALES COMO RECHAZO DE ÓRGANOS, SÍNDROME AUTOINMUNE<br /> INCLUYENDO ARTRITIS REUMATOIDE, ESCLEROSIS MÚLTIPLE, COLITIS ULCERANTE, ASMA, ENTRE OTRAS. COMPOUNDS DERIVED FROM PYRIDINE, FROM FORMULA (I) IN WHICH A, R1, R2, R3 AND R4 ARE AS DEFINED IN THE DESCRIPTIVE MEMORY AND CLAIMS SPECIFICATIONS, AGONISTS OF THE SLP1 / EDG1 RECEIVER; PHARMACEUTICAL COMPOSITION AND USE IN THE TREATMENT OF DISEASES OR DISORDERS SUCH AS ORGAN REJECTION, AUTOIMMUNE SYNDROME <br /> INCLUDING RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS, ULCERATING COLITIS, OR ASTHMA, BETWEEN.
CL2012000101A2009-07-162012-01-13
Pyridine derived compounds, s1p1 / edg1 receptor agonists, pharmaceutical composition; use of the compound for the treatment of diseases or disorders associated with the activated immune system such as organ rejection, autoimmune syndromes including rheumatoid arthritis, among others.
CL2012000101A1
(en)
Pyridine derived compounds, s1p1 / edg1 receptor agonists, pharmaceutical composition; use of the compound for the treatment of diseases or disorders associated with the activated immune system such as organ rejection, autoimmune syndromes including rheumatoid arthritis, among others.
Substituted c20-21 steroid derived compounds, glucocorticoid receptor agonists; pharmaceutical composition comprising said compound; and use to treat or prevent an immune, autoimmune, or inflammatory disease or condition, such as inflammatory colitis and rheumatoid arthritis.
Compounds derived from substituted benzoylamino-indan-2-carboxylic acids, inhibitors of the cxcr5 receptor; pharmaceutical composition; and its use in the treatment of inflammatory physiological effects, such as rheumatoid arthritis and asthma.
Substituted pyridine or pyridazine derived compounds, kinase inhibitors; pharmaceutical composition; and use for the treatment of an inflammatory and / or autoimmune condition such as rheumatoid arthritis.
Compounds derived from pyrrolopyrimidine, such as kinase inhibitors; pharmaceutical composition comprising them, useful for the treatment of an autoimmune disease or condition such as rheumatoid arthritis or lupus, and for the treatment of a heteroimmune or inflammatory disease or condition.
Triazolone-derived compounds, such as mpges-1 inhibitors; process of preparing said compounds; pharmaceutical composition that includes them, useful for the treatment of inflammation, asthma, epoc, arthritis, parkinson's disease and autoimmune diseases, among other diseases.
Compounds derived from aminopyrazoloquinazolines, as inhibitors against the phosphorylating activity of the igf-1 receptor located in cell membranes; pharmaceutical preparation that contains them; and its use in the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.
Compounds derived from amino-pyrazine, kinase-pi 3 inhibitors; pharmaceutical composition; and use for the treatment of inflammatory or allergic conditions, such as respiratory diseases, rheumatoid arthritis, ulcerative colitis, among others.
COMPOUNDS DERIVED FROM HETEROARIL-CARBOXAMIDA, ANTAGONISTS OF THE CHEMIOQUINE RECEPTOR; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OR PREVENTION OF SUCH DISEASES AS REJECTION OF ORGAN TRANSPLANTS, Rheumatoid Arthritis, LUPUS, ENTR
Compounds derived from pyrazolopyridine; Preparation process; Pharmaceutical composition and use in the treatment of diseases such as rheumatoid arthritis, psoriasis, multiple sclerosis, among others.
Pyridin-2-yl derived compounds; s1p1 / edg1 receptor agonist; pharmaceutical composition comprising them; use in disorders associated with the immune system.
Compounds derived from thioethers c-21, glucocorticoid receptor agonists; pharmaceutical composition; and use for the treatment or prophylaxis of an immune, autoimmune or inflammatory disease or condition, such as rheumatoid arthritis and multiple sclerosis.